Press briefing on the conclusion of the investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events by the Pharmacovigilance Risk Assessment Committee (PRAC)
EMA is holding a virtual press briefing on the conclusion of the evaluation of a safety signal with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) relating to cases of thromboembolic events by EMA’s safety committee (PRAC) on 18 March 2021.
- Emer Cooke (Executive Director)
- Sabine Straus (Chair of PRAC)
- Peter Arlett (Head of Data Analytics and Methods Task Force)
The press briefing will be moderated by Marie-Agnes Heine (Head of Communication). The press briefing will be held in English.